N/A
N=30
Training Attention and Eye Movement in ASD
Autistic Disorder · Autism Spectrum Disorder
Bottom Line
View on ClinicalTrials.gov: NCT02403817 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Spatial Attention Baseline — 80.3; 43.0 Percent Correct
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cognitive Training (Behavioral); Eye Motor Training (Behavioral); Hand Motor Training (Behavioral)
- Age
- Pediatric, Adult · 9+ yrs
- Sex
- All
- Sponsor
- University of California, San Diego
- Primary completion
- Aug 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Spatial Attention Baseline |
80.3; 43.0 | — |
| PRIMARY Saccadic Eye Movements Baseline |
49.20 | — |
| PRIMARY Change in Spatial Attention at 8 Weeks |
88.07; 77.5 | 0.00005 sig |
| PRIMARY Change in Saccadic Eye Movements at 8 Weeks |
59.4 | 0.018 sig |
Summary
Current therapies for autism target social and language behaviors, but due to the high-level nature of these skills any improvement rarely extends beyond the targeted behavior. This project uses new technology to implement a novel concept for behavioral intervention to improve basic attention and eye movement skills in ASD. Because these basic skills form the foundation for good social communication, training these abilities has the potential to improve a broad spectrum of clinical symptoms, and in young children may affect the course of development.
Eligibility Criteria
Inclusion Criteria
- Participant has a diagnosis of Autism Spectrum Disorder (on Diagnostic and Statistical Manual -IV, Autism Diagnostic Observation Schedule, Autism Diagnostic Interview-Revised)
- Participant has a nonverbal Intelligence Quotient (IQ) of 85 or greater and verbal IQ of 70 or greater
- Cooperative and able to follow instructions
- Normal hearing acuity
- Normal or corrected-to-normal vision
Exclusion Criteria
- Major medical or neurological problems including seizures, diagnosed epileptiform EEG abnormalities, migraine, tuberous sclerosis, fragile X, static encephalopathies resulting from prior Central Nervous System insults, significant premature birth, and history of exposure to teratogens, metabolic abnormalities, and history of head trauma, cerebral palsy, stroke, meningitis, brain tumor or additional psychiatric diagnoses
- Participants currently participating in vision therapy will be excluded
Data sourced from ClinicalTrials.gov (NCT02403817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.